10-Q
Quarterly Report
ADIAL PHARMACEUTICALS, INC.
ADIL
NASDAQ
CIK: 1513525
File #: 001-38323
Balance Sheet
23 line items · 2 periods
XBRL
| Item | Sep 30, 2025 | Dec 31, 2024 |
|---|---|---|
Current Assets: | ||
Cash and cash equivalents | 4,606,289 | 3,750,525 |
Prepaid expenses and other current assets | 407,543 | 308,239 |
Total Current Assets | 5,013,832 | 4,058,764 |
Intangible assets, net | 2,925 | 3,348 |
Equity method investment | 643,090 | 981,830 |
Equity Method Investments | 643,090 | 981,830 |
Total Assets | 5,659,847 | 5,043,942 |
Current Liabilities: | ||
Accounts payable | 556,284 | 250,130 |
Related Party | — | 48,272 |
Accrued expenses | 598,472 | 677,456 |
Total Current Liabilities | 1,154,756 | 975,858 |
Total Liabilities | 1,154,756 | 975,858 |
Stockholders’ Equity | ||
Common Stock, 100,000,000 shares authorized with a par value of $0.001 per share, 23,836,383 and 6,474,588 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 23,836 | 6,473 |
Additional paid in capital | 92,457,586 | 86,056,934 |
Accumulated deficit | (87,976,331) | (81,995,323) |
Total Stockholders’ Equity | 4,505,091 | 4,068,084 |
Common Stock | 23,836 | 6,473 |
Additional Paid In Capital | 92,457,586 | 86,056,934 |
Accumulated Deficit | (87,976,331) | (81,995,323) |
Total Liabilities and Stockholders’ Equity | 5,659,847 | 5,043,942 |